Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M153,319Revenue $M24,890Net Margin (%)48.6Z-Score7.9
Enterprise Value $M155,988EPS $7.4Operating Margin %61.3F-Score8
P/E(ttm))14.0Cash Flow Per Share $4.3Pre-tax Margin (%)59.7Higher ROA y-yY
Price/Book10.110-y EBITDA Growth Rate %0Quick Ratio2.8Cash flow > EarningsY
Price/Sales6.85-y EBITDA Growth Rate %27.2Current Ratio3.1Lower Leverage y-yN
Price/Cash Flow17.4y-y EBITDA Growth Rate %246ROA % (ttm)41.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)86.6Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M1,489ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDKen Heebner 2014-12-31 Sold Out -4.7%$89.45 - $114.22
($103.4)
$ 102.94-0%Sold Out0
GILDJulian Robertson 2014-12-31 Add1.67%$89.45 - $114.22
($103.3)
$ 102.94-0%Add 20.27%533,911
GILDLeon Cooperman 2014-12-31 Buy 0.96%$89.45 - $114.22
($103.54)
$ 102.94-1%New holding612,500
GILDJean-Marie Eveillard 2014-12-31 Add0.3%$89.45 - $114.22
($103.4)
$ 102.94-0%Add 328672.00%1,315,088
GILDJoel Greenblatt 2014-12-31 Add0.26%$89.45 - $114.22
($103.3)
$ 102.94-0%Add 51.98%1,009,462
GILDRonald Muhlenkamp 2014-12-31 Add0.24%$89.45 - $114.22
($103.4)
$ 102.94-0%Add 6.10%218,945
GILDJohn Rogers 2014-12-31 Add0.17%$89.45 - $114.22
($103.4)
$ 102.94-0%Add 24.68%802,803
GILDVanguard Health Care Fund 2014-12-31 Sold Out -0.1%$89.45 - $114.22
($103.4)
$ 102.94-0%Sold Out0
GILDMariko Gordon 2014-12-31 Sold Out -0.05%$89.45 - $114.22
($103.3)
$ 102.94-0%Sold Out0
GILDDavid Dreman 2014-12-31 Sold Out -0.02%$89.45 - $114.22
($103.3)
$ 102.94-0%Sold Out0
GILDRonald Muhlenkamp 2014-09-30 Add1.19%$85.07 - $109.43
($97.98)
$ 102.945%Add 42.59%206,350
GILDKen Heebner 2014-09-30 Reduce-0.33%$85.07 - $109.43
($97.98)
$ 102.945%Reduce -8.77%1,560,000
GILDVanguard Health Care Fund 2014-09-30 Reduce-0.28%$85.07 - $109.43
($97.98)
$ 102.945%Reduce -76.79%379,200
GILDJoel Greenblatt 2014-09-30 Add0.21%$85.07 - $109.43
($97.98)
$ 102.945%Add 42.28%664,223
GILDKen Fisher 2014-09-30 Reduce-0.04%$85.07 - $109.43
($97.98)
$ 102.945%Reduce -21.74%763,423
GILDDavid Dreman 2014-09-30 Buy 0.02%$85.07 - $109.43
($97.98)
$ 102.945%New holding2,388
GILDDodge & Cox 2014-09-30 Buy $85.07 - $109.43
($97.98)
$ 102.945%New holding4,800
GILDKen Heebner 2014-06-30 Buy 3.8%$65.48 - $83.02
($77.76)
$ 102.9424%New holding1,710,000
GILDJulian Robertson 2014-06-30 Add2.98%$65.48 - $83.02
($77.76)
$ 102.9424%Add 28.55%443,911
GILDRonald Muhlenkamp 2014-06-30 Reduce-0.59%$65.48 - $83.02
($77.76)
$ 102.9424%Reduce -24.63%144,715
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-04-15Sell70,000$103.841.32view
Carter Paul RutherfordEVP Commercial Ops 2015-04-08Sell1,000$1005.21view
Alton Gregg HEVP, Corp & Med Affairs 2015-04-08Sell5,000$1005.21view
MARTIN JOHN CChairman and CEO 2015-04-01Sell150,000$96.748.76view
Alton Gregg HEVP, Corp & Med Affairs 2015-04-01Sell7,000$96.538.99view
Carter Paul RutherfordEVP Commercial Ops 2015-04-01Sell1,000$98.047.31view
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-03-16Sell70,000$100.84.38view
Whitley Richard JamesDirector 2015-03-02Sell5,000$103.431.72view
Carter Paul RutherfordEVP Commercial Ops 2015-03-02Sell2,000$104.180.99view
Alton Gregg HEVP, Corp & Med Affairs 2015-03-02Sell12,000$103.631.52view

Press Releases about GILD :

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Gilead Sciences Inc, CarMax Inc, Anthem Inc. Apr 20 2015 
Current positions Apr 13 2015 
Prescription Data Offers Insight Into Gilead Sciences' Sales Apr 08 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Weekly CEO Sells Highlight: Sprouts Farmers Market, Lions Gate Entertainment, AMN Healthcare Service Apr 05 2015 
My starred stocks Apr 05 2015 
sales growth Apr 03 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
UnitedHealth Planning Catamaran Corp’s Acquisition For $12.78 Billion Apr 02 2015 
Gilead’s Hep C Drug Receives Approval in Japan Mar 31 2015 


More From Other Websites
Biogen Earnings Preview: What To Look For Apr 23 2015
Most active Nasdaq-traded stocks Apr 23 2015
Gilead (GILD) Announces Encouraging Data on its HCV Drugs - Analyst Blog Apr 23 2015
Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Apr 23 2015
Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Apr 23 2015
Gilead to Use a Give-Away Program in Georgia for Reducing Hepatitis C Apr 23 2015
Midday Glance: Biotechnology companies Apr 23 2015
AbbVie Beats Q1 Estimates; Novartis, Alexion Mixed Apr 23 2015
AQR Capital More Than Doubles its Holdings in Gilead Sciences Apr 23 2015
1:19 am Gilead Sciences announces data for investigational, all-oral, pan-genotypic three-drug... Apr 23 2015
Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir,... Apr 23 2015
Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients... Apr 23 2015
Gilead Earnings Preview: What You Should Know Apr 22 2015
Forget Google: 5 Top Stocks With Earnings Thursday Apr 22 2015
Gilead Sciences (GILD) Stock Is the 'Chart of the Day' Apr 22 2015
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera... Apr 22 2015
Should Gilead Sciences Buy Vertex? Bernstein Says Yes, Maxim Says No Apr 21 2015
Gilead's Stock Spikes on Possibility of Vertex Deal Apr 21 2015
Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says Apr 21 2015
Time to take profits in biotech? Apr 21 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK